BOT IMAGE, INC.

Bot Image, Inc. is an FDA-cleared AI software company specializing in prostate cancer detection, screening, and diagnosis using bi-parametric MRI (bpMRI). The company's flagship product, ProstatID, is a CADe/CADx (Computer-Aided Detection and Diagnosis) software designed to assist radiologists in detecting, assessing, and characterizing prostate lesions suspicious for cancer. ProstatID is vendor-agnostic and integrates seamlessly with existing PACS systems from major OEMs (Philips, Siemens, GE) without requiring additional equipment or user intervention. The software delivers AI-generated results within minutes, providing physicians with lesion segmentation, risk scoring aligned to Gleason grades, and 3D visualization for treatment planning. Bot Image also offers MaleScan, a direct-to-patient/physician cloud-based service enabling rapid AI-assisted diagnostic reporting. The company's AI models are trained on over 1,000 biopsied cases with 6,000+ biopsy confirmation points, demonstrating significantly improved diagnostic accuracy and inter-reader agreement in clinical studies. Solutions address key pain points including interpretation complexity, reading time reduction, cost efficiency via non-contrast imaging, and improved clinical outcomes for prostate cancer screening and early detection.